BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

546 related articles for article (PubMed ID: 21830924)

  • 21. A Bayesian approach to the statistical analysis of device preference studies.
    Fu H; Qu Y; Zhu B; Huster W
    Pharm Stat; 2012; 11(2):149-56. PubMed ID: 22374584
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FDA perspective on clinical trial design for cardiovascular devices.
    Chen E; Sapirstein W; Ahn C; Swain J; Zuckerman B
    Ann Thorac Surg; 2006 Sep; 82(3):773-5. PubMed ID: 16928481
    [No Abstract]   [Full Text] [Related]  

  • 23. The FDA's role in medical device clinical studies of human subjects.
    Saviola J
    J Neural Eng; 2005 Mar; 2(1):S1-4. PubMed ID: 15876645
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An empirical Bayes approach to evaluation of results for a specific region in multiregional clinical trials.
    Huang Y; Chang WJ; Hsiao CF
    Pharm Stat; 2013; 12(2):59-64. PubMed ID: 23319408
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A closer look at combining data among a small number of binomial experiments.
    Malec D
    Stat Med; 2001 Jun; 20(12):1811-24. PubMed ID: 11406843
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evidence-based medicine and drug-eluting stents.
    O'Dwyer J
    Med Device Technol; 2004 May; 15(4):34-7. PubMed ID: 15303564
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FDA's perspectives on cardiovascular devices.
    Chen EA; Patel-Raman SM; O'Callaghan K; Hillebrenner MG
    J Cardiovasc Transl Res; 2009 Jun; 2(2):143-6. PubMed ID: 20559979
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adaptive methods: telling "the rest of the story".
    Emerson SS; Fleming TR
    J Biopharm Stat; 2010 Nov; 20(6):1150-65. PubMed ID: 21058111
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Premarket clinical evaluation of novel cardiovascular devices: quality analysis of premarket clinical studies submitted to the Food and Drug Administration 2000-2007.
    Kramer DB; Mallis E; Zuckerman BD; Zimmerman BA; Maisel WH
    Am J Ther; 2010; 17(1):2-7. PubMed ID: 20038828
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modernizing device regulation.
    Garber AM
    N Engl J Med; 2010 Apr; 362(13):1161-3. PubMed ID: 20335575
    [No Abstract]   [Full Text] [Related]  

  • 32. Pharmaceuticals and medical devices: medical devices. Issue brief.
    Health Policy Tracking Service, A Service of Thomson Reuters/West
    Issue Brief Health Policy Track Serv; 2011 Jan; ():1-24. PubMed ID: 21374838
    [No Abstract]   [Full Text] [Related]  

  • 33. Bayesian hierarchical modeling for detecting safety signals in clinical trials.
    Xia HA; Ma H; Carlin BP
    J Biopharm Stat; 2011 Sep; 21(5):1006-29. PubMed ID: 21830928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design and implementation of clinical trials in rehabilitation research.
    Hart T; Bagiella E
    Arch Phys Med Rehabil; 2012 Aug; 93(8 Suppl):S117-26. PubMed ID: 22840878
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bayesian adaptive clinical trials: a dream for statisticians only?
    Chevret S
    Stat Med; 2012 May; 31(11-12):1002-13. PubMed ID: 21905067
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The nightmare of FDA clearance/approval to market: perception or reality?
    Tylenda CA
    Technol Health Care; 1996 Sep; 4(3):259-67. PubMed ID: 8931236
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Medical device regulatory landscape: the imperative of finding balance.
    Kaplan AV; Williams DO
    Circ Cardiovasc Interv; 2012 Feb; 5(1):2-5. PubMed ID: 22337999
    [No Abstract]   [Full Text] [Related]  

  • 38. Pediatric cardiovascular safety: challenges in drug and device development and clinical application.
    Bates KE; Vetter VL; Li JS; Cummins S; Aguel F; Almond C; Dubin AM; Elia J; Finkle J; Hausner EA; Joseph F; Karkowsky AM; Killeen M; Lemacks J; Mathis L; McMahon AW; Pinnow E; Rodriguez I; Stockbridge NL; Stockwell M; Tassinari M; Krucoff MW
    Am Heart J; 2012 Oct; 164(4):481-92. PubMed ID: 23067905
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A predictive Bayesian approach to the design and analysis of bridging studies.
    Gould AL; Jin T; Zhang LX; Wang WW
    J Biopharm Stat; 2012 Sep; 22(5):916-34. PubMed ID: 22946940
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bayesian clinical trials.
    Berry DA
    Nat Rev Drug Discov; 2006 Jan; 5(1):27-36. PubMed ID: 16485344
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.